NCT02581280View on ClinicalTrials.gov

Population Pharmacokinetics of Teicoplanin, Levofloxacin, Piperacillin/Tazobactam, Meropenem, Vancomycin, Remifentanil, Cefepime, Cefpirome, Sufentanil, Midazolam, Clopidogrel, Ticagrelor, Prasugrel During Veno-arterial Extracorporeal Membrane Oxygenation (VA ECMO)

CompletedOBSERVATIONAL

Enrollment

Participants

Timeline

Start Date

December 31, 2014

Primary Completion Date

January 31, 2019

Study Completion Date

January 31, 2019

Conditions

Cardiac Dysfunction

Interventions

OTHER

Residual blood

Residual blood samples(1\~2 cc) at each sampling time are collected from all subjects while using ECMO for drug concentration assays(LC-MS/MS etc.).

Trial Locations (1)

03722

Division of Cardiology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul

All Listed Sponsors

lead

Yonsei University

OTHER

NCT02581280 - Population Pharmacokinetics of Teicoplanin, Levofloxacin, Piperacillin/Tazobactam, Meropenem, Vancomycin, Remifentanil, Cefepime, Cefpirome, Sufentanil, Midazolam, Clopidogrel, Ticagrelor, Prasugrel During Veno-arterial Extracorporeal Membrane Oxygenation (VA ECMO) | Biotech Hunter | Biotech Hunter